BP Heads to Court to Fight Fictitious Spill Claims

Joe Goldman |

BP’s (BP) legal team is in court on Monday, trying to fight millions of dollars in Deepwater Horizon oil spill-related payments that the company believes are fabricated and inflated.

The British oil giant believes that Patrick Juneau, who oversees the claims process, is approving millions of dollars in “fictitious” payments to people who do not deserve a settlement. A lower court previously refused to block such payments, so BP is now in the Court of Appeals in hopes to reverse the ruling.

“We ask the Fifth Circuit to follow established legal principles of contract law and interpret the agreement as written and intended: paying only those claimants who suffered actual losses,” said Geoeff Morrell, a BP spokesperson.



According to BP’s website, the company has distributed over $11 billion in claims from its $20 billion trust since 2010. However, according to the Birgmingham News, BP has already committed over $18.3 billion in funds, allotting only $1.7 billion for future claims. BP never established a hard cap on spill-related payments, so it could be on the hook for much more pending an unfavorable ruling from the court.

BP will accept claims until April of 2014. Unless the legal system works in its favor, the company could be liable for a blank check made out to gulf business owners.

BP shares traded slightly higher on Monday's news, rising one-tenth of a percent to $41.21. Shares are down more than four percent over the last month.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
BP BP p.l.c. 34.84 0.24 0.69 3,501,179 Trade

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.